Earning call transcript
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IOL Chemicals reported strong Q4 FY26 results with revenue of INR 619 crores (up 17.4% YoY) and EBITDA of INR 94 crores (up 40% YoY) with margins at 15.2%, the highest ever quarterly performance. For FY26, revenue stood at INR 2,319 crores with EBITDA margins improving to 12.4% from 10.7% in FY25. The company has a new 100-acre greenfield project near Bhatinda Highway with a planned investment of INR 1,200-1,400 crores over 4-5 years. Management guided for FY27 revenue growth of around 15% and EBITDA margins of 14-14.5%, funded through internal accruals at INR 200-250 crores annual capex. Capacity utilization is high across key products (85-95% for most APIs, 98-100% for chemicals), and the company targets increasing non-ibuprofen exports from 20% to 25% of pharma revenue.
The company demonstrated strong execution with margin improvement and capacity utilization gains, while signaling confidence in sustained growth through FY27 targets and a major greenfield expansion. The focus on non-Ibuprofen APIs and export market penetration could drive higher realizations going forward.